Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05855876
Other study ID # ROBRA
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date July 5, 2023
Est. completion date April 5, 2024

Study information

Verified date July 2023
Source Stella Center
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The purpose of this study is to examine measures of GrimAge clock in SOF members undergoing treatment for PTSD/TBI using CSB.


Description:

The primary objective of this study is to assess the impact of a combined protocol of subanesthetic ketamine infusions (SKI) and bilateral cervical sympathetic blocks (CSB) on aging, as measured by the GrimAge epigenetic clock. The secondary objective of this study is to assess the impact of this treatment paradigm on PTSD and mental health, as measured over a 6 month time period using the following questionnaires: Post-traumatic Stress Disorder Checklist (PCL-5), Patient Health Questionnaire 9 (PHQ-9), Depressive Symptom Index-Suicidality Subscale (DSI-SS), Generalized Anxiety Disorder 7-item (GAD-7), and Neurobehavioral Symptom Inventory (NSI). The tertiary objectives of the study are to investigate if PTSD is associated with significantly reduced free testosterone levels and increased C-reactive protein (CRP) levels.


Recruitment information / eligibility

Status Recruiting
Enrollment 20
Est. completion date April 5, 2024
Est. primary completion date April 5, 2024
Accepts healthy volunteers No
Gender All
Age group 40 Years to 60 Years
Eligibility Inclusion Criteria: - Recruited from SOF with an active duty history of at least 5 years. - Subjects may be in active duty or retired, male and female, between the ages of 40 and 60 years old. - The participants must have a confirmed diagnosis of PTSD, identified by Posttraumatic Stress Disorder Checklist for DSM-5 (PCL-5) scores higher than 40. - The participants must have been on a stable pharmacological or psychotherapeutic therapy for at least three months (if applicable), and continue this treatment throughout the duration of the study. - They must be able and willing to consent for the study. Individuals who are able to become pregnant must adhere to a medically accepted method of contraception (eg. hormonal birth control, barrier birth control, intrauterine device, abstinence). Exclusion Criteria: - Existing Horner syndrome; - Allergy to local anesthetics or contrast; - Previous history of stellate ganglion block with psychosis; - Admission to in-patient psychiatric facility within last 3 months; - History of moderate of severe TBI; - Currently pregnant or breastfeeding; - Current substance use disorder, or test positive for 1 or more illegal or controlled drugs on the initial urine drug screen, such as cocaine, marijuana, amphetamines, opioids, benzodiazepines, amongst others; - Previous behavioral health diagnoses (bipolar I, psychosis, etc); - Currently undergoing exposure therapy.

Study Design


Intervention

Procedure:
subanesthetic ketamine infusions and bilateral cervical sympathetic blocks
Combined protocol of subanesthetic ketamine infusions and bilateral cervical sympathetic blocks

Locations

Country Name City State
United States Stella Center Westmont Illinois

Sponsors (1)

Lead Sponsor Collaborator
Stella Center

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change from baseline in Epigenetic Aging at 15 days GrimAge epigenetic clock tool to assess DNA methylation day 15
Primary Change from baseline in Epigenetic Aging at 90 days GrimAge epigenetic clock tool to assess DNA methylation day 90
Primary Change from baseline in Epigenetic Aging at 180 days GrimAge epigenetic clock tool to assess DNA methylation day 180
Secondary Change from baseline in Post-Traumatic Stress Disorder (PTSD) symptoms at 15 days Post-traumatic Stress Disorder Checklist (PCL-5), a 20-item self-report measure yielding a total symptom severity score between 0 and 80. day 15
Secondary Change from baseline in Post-Traumatic Stress Disorder (PTSD) symptoms at 90 days Post-traumatic Stress Disorder Checklist (PCL-5), a 20-item self-report measure yielding a total symptom severity score between 0 and 80. day 90
Secondary Change from baseline in Post-Traumatic Stress Disorder (PTSD) symptoms at 180 days Post-traumatic Stress Disorder Checklist (PCL-5), a 20-item self-report measure yielding a total symptom severity score between 0 and 80. day 180
Secondary Change from baseline in Depression at 15 days Patient Health Questionnaire 9 (PHQ-9), a 9-item self-report measure yielding a depression severity score between 0 and 27. day 15
Secondary Change from baseline in Depression at 90 days Patient Health Questionnaire 9 (PHQ-9), a 9-item self-report measure yielding a depression severity score between 0 and 27. day 90
Secondary Change from baseline in Depression at 180 days Patient Health Questionnaire 9 (PHQ-9), a 9-item self-report measure yielding a depression severity score between 0 and 27. day 180
Secondary Change from baseline in Suicidal Ideation at 15 days Depressive Symptom Index-Suicidality Subscale (DSI-SS), a 4-item self-report measure yielding a suicidal ideation severity score between 0 and 12. day 15
Secondary Change from baseline in Suicidal Ideation at 90 days Depressive Symptom Index-Suicidality Subscale (DSI-SS), a 4-item self-report measure yielding a suicidal ideation severity score between 0 and 12. day 90
Secondary Change from baseline in Suicidal Ideation at 180 days Depressive Symptom Index-Suicidality Subscale (DSI-SS), a 4-item self-report measure yielding a suicidal ideation severity score between 0 and 12. day 180
Secondary Change from baseline in Anxiety at 15 days Generalized Anxiety Disorder 7-item (GAD-7), a 7-item self-report measure yielding an anxiety severity score between 0 and 21. day 15
Secondary Change from baseline in Anxiety at 90 days Generalized Anxiety Disorder 7-item (GAD-7), a 7-item self-report measure yielding an anxiety severity score between 0 and 21. day 90
Secondary Change from baseline in Anxiety at 180 days Generalized Anxiety Disorder 7-item (GAD-7), a 7-item self-report measure yielding an anxiety severity score between 0 and 21. day 180
Secondary Change from baseline in Post-Concussion Symptom Severity at 15 days Neurobehavioral Symptom Inventory (NSI), a 22-item self-report measure yielding a post-concussion symptom severity score between 0 and 88. day 15
Secondary Change from baseline in Post-Concussion Symptom Severity at 90 days Neurobehavioral Symptom Inventory (NSI), a 22-item self-report measure yielding a post-concussion symptom severity score between 0 and 88. day 90
Secondary Change from baseline in Post-Concussion Symptom Severity at 180 days Neurobehavioral Symptom Inventory (NSI), a 22-item self-report measure yielding a post-concussion symptom severity score between 0 and 88. day 180
Secondary Change from baseline in Free testosterone levels at 15 days Quest diagnostics to measure Free testosterone levels day 15
Secondary Change from baseline in Free testosterone levels at 90 days Quest diagnostics to measure Free testosterone levels day 90
Secondary Change from baseline in Free testosterone levels at 180 days Quest diagnostics to measure Free testosterone levels day 180
Secondary Change from baseline in C-reactive protein (CRP) levels at 15 days Quest diagnostics to measure C-reactive protein (CRP) levels day 15
Secondary Change from baseline in C-reactive protein (CRP) levels at 90 days Quest diagnostics to measure C-reactive protein (CRP) levels day 90
Secondary Change from baseline in C-reactive protein (CRP) levels at 180 days Quest diagnostics to measure C-reactive protein (CRP) levels day 180
See also
  Status Clinical Trial Phase
Terminated NCT03052712 - Validation and Standardization of a Battery Evaluation of the Socio-emotional Functions in Various Neurological Pathologies N/A
Recruiting NCT05503316 - The Roll of Balance Confidence in Gait Rehabilitation in Persons With a Lesion of the Central Nervous System N/A
Completed NCT04356963 - Adjunct VR Pain Management in Acute Brain Injury N/A
Completed NCT03418129 - Neuromodulatory Treatments for Pain Management in TBI N/A
Terminated NCT03698747 - Myelin Imaging in Concussed High School Football Players
Recruiting NCT05130658 - Study to Improve Ambulation in Individuals With TBI Using Virtual Reality -Based Treadmill Training N/A
Recruiting NCT04560946 - Personalized, Augmented Cognitive Training (PACT) for Service Members and Veterans With a History of TBI N/A
Completed NCT05160194 - Gaining Real-Life Skills Over the Web N/A
Recruiting NCT02059941 - Managing Severe Traumatic Brain Injury (TBI) Without Intracranial Pressure Monitoring (ICP) Monitoring Guidelines N/A
Recruiting NCT03940443 - Differences in Mortality and Morbidity in Patients Suffering a Time-critical Condition Between GEMS and HEMS
Recruiting NCT03937947 - Traumatic Brain Injury Associated Radiological DVT Incidence and Significance Study
Completed NCT04465019 - Exoskeleton Rehabilitation on TBI
Recruiting NCT04530955 - Transitioning to a Valve-Gated Intrathecal Drug Delivery System (IDDS) N/A
Recruiting NCT03899532 - Remote Ischemic Conditioning in Traumatic Brain Injury N/A
Suspended NCT04244058 - Changes in Glutamatergic Neurotransmission of Severe TBI Patients Early Phase 1
Completed NCT03307070 - Adapted Cognitive Behavioral Treatment for Depression in Patients With Moderate to Severe Traumatic Brain Injury N/A
Recruiting NCT04274777 - The Relationship Between Lipid Peroxidation Products From Traumatic Brain Injury and Secondary Coagulation Disorders
Withdrawn NCT05062148 - Fundamental and Applied Concussion Recovery Modality Research and Development: Applications for the Enhanced Recovery N/A
Withdrawn NCT04199130 - Cognitive Rehabilitation and Brain Activity of Attention-Control Impairment in TBI N/A
Withdrawn NCT03626727 - Evaluation of the Efficacy of Sodium Oxybate (Xyrem®) in Treatment of Post-traumatic Narcolepsy and Post-traumatic Hypersomnia Early Phase 1